Aarti Pharmalabs has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a standalone net profit of ₹6,203.07 lakhs for the March quarter and ₹17,620.20 lakhs for the full year. Furthermore, the Board of Directors has recommended a final dividend of ₹2 per equity share (40% of face value) for the fiscal year 2025-26, subject to shareholder approval at the upcoming annual general meeting.
Financial Performance Overview
For the financial year ended March 31, 2026, Aarti Pharmalabs achieved a standalone total income of ₹181,287.50 lakhs, compared to ₹178,414.86 lakhs in the previous year. The standalone net profit for the year stood at ₹17,620.20 lakhs. On a consolidated basis, the company reported a total income of ₹182,918.89 lakhs and a net profit attributable to company owners of ₹17,470.73 lakhs for the same period.
Dividend Recommendation
Reflecting its commitment to delivering value to shareholders, the Board of Directors has recommended a final dividend of ₹2 per equity share on shares with a face value of ₹5 each for the financial year ended March 31, 2026. This recommendation is subject to the approval of shareholders at the company’s next Annual General Meeting.
Leadership and Governance Updates
During the board meeting held on May 25, 2026, several key administrative appointments were confirmed to strengthen the leadership team:
- Cost Auditor: Smt. Ketki D. Visariya has been re-appointed for the financial year 2026–27.
- Internal Auditor: The firm Manish Modi & Associates has been re-appointed for the financial year 2026–27.
- Senior Management: Mr. Sachin Patil (Head – Exports) and Mr. Rajendra Pagare (Head – Operations & Compliance) have been designated as Senior Management Personnel, effective May 25, 2026.
Operational Notes
The company noted an accounting adjustment regarding a target redemption forward contract entered during FY 2024-25. This derivative was previously omitted from fair value calculations; however, the impact has been recognized in the financial statements for the year ended March 31, 2026, and comparative quarterly figures have been restated to ensure transparency and accurate reporting.
Source: BSE
